REGENERON PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

08 Apr 2025 10:12:54 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

07 Apr 2025 06:45:03 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 Apr 2025 06:46:04 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

03 Apr 2025 13:08:52 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 Apr 2025 06:45:07 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

01 Apr 2025 11:45:14 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

31 Mar 2025 06:50:37 By NetDania Notify

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

27 Mar 2025 23:00:14 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 Mar 2025 06:46:28 By NetDania Notify

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

25 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

25 Mar 2025 11:10:05 By NetDania Notify

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

11 Mar 2025 18:32:16 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

08 Mar 2025 10:00:00 By Nasdaq GlobeNewswire

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

28 Feb 2025 04:00:02 By Nasdaq GlobeNewswire

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

26 Feb 2025 04:00:19 By Nasdaq GlobeNewswire

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

24 Feb 2025 12:00:04 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

17 Feb 2025 21:59:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

11 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

11 Feb 2025 04:00:39 By Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

08 Feb 2025 14:40:16 By Nasdaq GlobeNewswire